All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ocular involvement occurs in more than half of patients with chronic graft-versus-host disease (GvHD) after allogeneic hematopoietic cell transplantation (HCT), associating with poor prognosis.1 Yoshihiro Inamoto from the Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, and colleagues analyzed ocular GvHD, in collaboration with transplant hematologists and ophthalmologists, on behalf of the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. The expert review was published ahead of print in Biology of Blood and Marrow Transplantation.2
Recent updates in ocular GvHD, regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment were included and assessed in this analysis.
The authors concluded that “future research should be directed towards establishing reliable and widely-available tools for diagnosis and response measurement of ocular GvHD.”
References